Translating Antisense Technology into a Treatment for Huntington’s Disease-Reference-Cited by-同舟云学术

Translating Antisense Technology into a Treatment for Huntington’s Disease

Published:2018 Issue: Volume: Page:497-523
ISSN:1064-3745
Container-title:Methods in Molecular Biology
language:
Short-container-title:

Author:

Lane Roger M.,Smith Anne,Baumann Tiffany,Gleichmann Marc,Norris Dan,Bennett C. Frank,Kordasiewicz Holly

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-1-4939-7825-0_23

Reference116 articles.

1. Becker RE, Greig NH (2014) A new regulatory road-map for Alzheimer’s disease drug development. Curr Alzheimer Res 11:215–220

2. Dubois B, Feldman HH, Jacova C et al (2007) Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6:734–746

3. Zielonka D, Mielcarek M, Landwehrmeyer GB (2015) Update on Huntington’s disease: advances in care and emerging therapeutic options. Parkinsonism Relat Disord 21:169–178

4. Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington’s disease: what’s in the pipeline? Mov Disord 29:1434–1445

5. Leavitt B, Kordasiewicz TS, Landwehrmeyer B et al (2016) Discovery and early clinical development of ISIS-HTTRx the first HTT-lowering drug to be tested in patients with Huntington’s disease. Neurology 86(16 Suppl):PL01.002

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BDNF and TRiC-inspired reagent rescue cortical synaptic deficits in a mouse model of Huntington's disease;Neurobiology of Disease;2024-06

2. General and Specific Cytotoxicity of Chimeric Antisense Oligonucleotides in Bacterial Cells and Human Cell Lines;Antibiotics;2024-01-26

3. Evaluating the efficacy of purchased antisense oligonucleotides to reduce mouse and human tau in vivo;Frontiers in Molecular Neuroscience;2023-12-18

4. Nanomedicine based strategies for oligonucleotide traversion across the blood–brain barrier;Journal of Controlled Release;2023-02

5. Evaluating the efficacy of commercially available antisense oligonucleotides to reduce mouse and human tauin vivo;2022-12-29